Cargando…

Palivizumab immunoprophylaxis for infants with BPD has medium- and long-term benefits: myth or maxim?

It is uncertain whether immunoprophylaxis against RSV protects preterm babies with BPD against future respiratory problems. It is biologically plausible that it does, at least in some infants. https://bit.ly/3ikzwZD

Detalles Bibliográficos
Autores principales:	Quinn, Lauren A., Hirani, Sunaya H., Williams, Thomas C., Sinha, Ian P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Respiratory Society 2021
Materias:	Viewpoint
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8753667/ https://www.ncbi.nlm.nih.gov/pubmed/35035568 http://dx.doi.org/10.1183/20734735.0110-2021

Ejemplares similares

Effectiveness of palivizumab immunoprophylaxis in preterm infants against respiratory syncytial virus disease in Qatar
por: Abushahin, Ahmad, et al.
Publicado: (2018)

A Systematic Review of Compliance with Palivizumab Administration for RSV Immunoprophylaxis
por: Frogel, Michael
Publicado: (2010)

Compliance with The RSV Immunoprophylaxis Dosing Schedule in The Polish Registry for Palivizumab (2008-2014)
por: Borecka, Róża, et al.
Publicado: (2019)

Should we use Palivizumab immunoprophylaxis for infants against respiratory syncytial virus? – a cost-utility analysis
por: Ginsberg, Gary M., et al.
Publicado: (2018)

Molecular characterization of respiratory syncytial viruses infecting children reported to have received palivizumab immunoprophylaxis
por: Oliveira, Danielle B.L., et al.
Publicado: (2015)

Respiratory Syncytial Virus Immunoprophylaxis with Palivizumab: 12-Year Observational Study of Usage and Outcomes in Canada
por: Mitchell, Ian, et al.
Publicado: (2021)

Macrolides (alone or in combination) should be used as first-line empirical therapy of community-acquired pneumonia in children: myth or maxim?
por: Warris, Adilia
Publicado: (2021)

BPD, Not BPD, or Iatrogenic BPD: Findings of Lung Ultrasound Examinations
por: Liu, Jing, et al.
Publicado: (2014)

Effectiveness of palivizumab immunoprophylaxis to prevent respiratory syncytial virus hospitalizations in healthy full-term <6-month-old infants from the circumpolar region of Nunavik, Quebec, Canada
por: Gilca, Rodica, et al.
Publicado: (2020)

Oxygen-induced hypercapnia in COPD: myths and facts
por: Abdo, Wilson F, et al.
Publicado: (2012)

It’s Time to Dispel the Myth of “Asymptomatic” Schistosomiasis
por: King, Charles H.
Publicado: (2015)

The myth of psychological debriefings during the corona pandemic
por: Van Overmeire, Roel
Publicado: (2020)

Incidence of respiratory syncytial virus infection in children with congenital heart disease undergoing immunoprophylaxis with palivizumab in Pará state, north region of Brazil
por: de Souza, Roseane Porfírio, et al.
Publicado: (2019)

Platelet-Rich Plasma in Androgenic Alopecia: Myth or an Effective Tool
por: Khatu, Swapna S, et al.
Publicado: (2014)

The myth of generalisability in clinical research and machine learning in health care
por: Futoma, Joseph, et al.
Publicado: (2020)

Falls Detection and Prevention Systems in Home Care for Older Adults: Myth or Reality?
por: Pech, Marion, et al.
Publicado: (2021)

Impact of the Withdrawal of Palivizumab Immunoprophylaxis on the Incidence of Respiratory Syncytial Virus (RSV) Hospitalizations Among Infants Born at 33 to 35 Weeks’ Gestational Age in the Province of Quebec, Canada: The RSV-Quebec Study
por: Papenburg, Jesse, et al.
Publicado: (2020)

The myth that Nigerians are immune to SARS-CoV-2 and that COVID-19 is a hoax are putting lives at risk
por: Aiyewumi, Oluwadamilola, et al.
Publicado: (2020)

Refining contextual inquiry to maximize generalizability and accelerate the implementation process
por: Davis, Molly, et al.
Publicado: (2021)

Bronchopulmonale Dysplasie (BPD)
por: Herting, E.
Publicado: (2013)

Myths and maxims in paediatric respiratory medicine
por: Bhatt, Jayesh M., et al.
Publicado: (2018)

Predicting BPD: Lessons Learned From the Airway Microbiome of Preterm Infants
por: Gentle, Samuel J., et al.
Publicado: (2020)

The Medicaid Cost of Palivizumab
por: Ambrose, Christopher S., et al.
Publicado: (2015)

Consumer perspective from people with a diagnosis of Borderline Personality Disorder (BPD) on BPD management—How are the Australian NHMRC BPD guidelines faring in practice?
por: Proctor, Jessica Margot, et al.
Publicado: (2020)

Time to Have Effective Regulation of the Mental Health Apps Market: Maximize Gains and Minimize Harms
por: Singh, Swarndeep, et al.
Publicado: (2022)

Safety and pharmacokinetics of extended use of palivizumab in Saudi Arabian infants and children
por: al-Alaiyan, Saleh, et al.
Publicado: (2015)

Has the NTD Community Neglected Evidence-Based Policy?
por: Nagpal, Sukrti, et al.
Publicado: (2013)

Has Your Physician Heard of Williams-Beuren Syndrome?
por: Alquran, Lance, et al.
Publicado: (2020)

Airway Microbial Community Turnover Differs by BPD Severity in Ventilated Preterm Infants
por: Wagner, Brandie D., et al.
Publicado: (2017)

Undertesting of COVID-19 in Indonesia: what has gone wrong?
por: van Empel, Giovanni, et al.
Publicado: (2020)

Working in Venezuela: How the Crisis has Affected the Labor Conditions
por: Caraballo-Arias, Yohama, et al.
Publicado: (2018)

How the COVID-19 pandemic has affected rheumatology research
por: Moreyra, Paula Alba, et al.
Publicado: (2022)

Mental health literacy and borderline personality disorder (BPD): what do the public “make” of those with BPD?
por: Furnham, Adrian, et al.
Publicado: (2014)

Systemic Steroids in Preventing Bronchopulmonary Dysplasia (BPD): Neurodevelopmental Outcome According to the Risk of BPD in the EPICE Cohort
por: Zayat, Noura, et al.
Publicado: (2022)

Passive Broad-Spectrum Influenza Immunoprophylaxis
por: Berry, Cassandra M., et al.
Publicado: (2014)

AAV Vectored Immunoprophylaxis for Filovirus Infections
por: Rghei, Amira D., et al.
Publicado: (2020)

Biomarkers for systemic lupus erythematosus: has the right time finally arrived?
por: Mittleman, Barbara B
Publicado: (2004)

What Has Shaken the Determination of Medical Students to Become a Doctor?
por: Xu, Xin-Ye, et al.
Publicado: (2017)

Review of palivizumab in the prophylaxis of respiratory syncytial virus (RSV) in high-risk infants
por: Mejías, Asunción, et al.
Publicado: (2008)

Respiratory Syncytial Virus Infection in High-risk Infants – an Update on Palivizumab Prophylaxis
por: Resch, Bernhard
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_62o54odkanjo7j844lsgcvfi5i